Merck Gets CHMP Positive Opinion For KEYTRUDA For Advanced Non-Small Cell Lung Cancer Treatment

By: via Benzinga
Merck & Co., Inc. (NYSE: MRK) disclosed Monday that the Committee for Medicinal Products for Human Use (CHMP) of the European ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.